Literature DB >> 9988164

Human infection due to Ebola virus, subtype Côte d'Ivoire: clinical and biologic presentation.

P Formenty1, C Hatz, B Le Guenno, A Stoll, P Rogenmoser, A Widmer.   

Abstract

In November 1994 after 15 years of epidemiologic silence, Ebola virus reemerged in Africa and, for the first time, in West Africa. In Côte d'Ivoire, a 34-year-old female ethologist was infected while conducting a necropsy on a wild chimpanzee. Eight days later, the patient developed a syndrome that did not respond to antimalarial drugs and was characterized by high fever, headache, chills, myalgia, and cough. The patient had abdominal pain, diarrhea, vomiting, and a macular rash, and was repatriated to Switzerland. The patient suffered from prostration and weight loss but recovered without sequelae. Laboratory findings included aspartate aminotransferase and alanine aminotransferase activity highly elevated, thrombocytopenia, lymphopenia, and, subsequently, neutrophilia. A new subtype of Ebola was isolated from the patient's blood on days 4 and 8. No serologic conversion was detected among contact persons in Côte d'Ivoire (n = 22) or Switzerland (n = 52), suggesting that infection-control precautions were satisfactory.

Entities:  

Mesh:

Year:  1999        PMID: 9988164     DOI: 10.1086/514285

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  72 in total

1.  A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Authors:  Jin Huk Choi; Stephen C Schafer; Lihong Zhang; Gary P Kobinger; Terry Juelich; Alexander N Freiberg; Maria A Croyle
Journal:  Mol Pharm       Date:  2011-12-15       Impact factor: 4.939

Review 2.  Laboratory diagnostic systems for Ebola and Marburg hemorrhagic fevers developed with recombinant proteins.

Authors:  Masayuki Saijo; Masahiro Niikura; Tetsuro Ikegami; Ichiro Kurane; Takeshi Kurata; Shigeru Morikawa
Journal:  Clin Vaccine Immunol       Date:  2006-04

Review 3.  Ebola virus disease.

Authors:  Nicholas J Beeching; Manuel Fenech; Catherine F Houlihan
Journal:  BMJ       Date:  2014-12-10

4.  Immunofluorescence method for detection of Ebola virus immunoglobulin g, using HeLa cells which express recombinant nucleoprotein.

Authors:  M Saijo; M Niikura; S Morikawa; I Kurane
Journal:  J Clin Microbiol       Date:  2001-02       Impact factor: 5.948

Review 5.  Achieving cross-reactivity with pan-ebolavirus antibodies.

Authors:  Liam B King; Jacob C Milligan; Brandyn R West; Sharon L Schendel; Erica Ollmann Saphire
Journal:  Curr Opin Virol       Date:  2019-03-15       Impact factor: 7.090

Review 6.  Gastrointestinal and Hepatic Manifestations of Ebola Virus Infection.

Authors:  Nisha Sharma; Mitchell S Cappell
Journal:  Dig Dis Sci       Date:  2015-05-14       Impact factor: 3.199

Review 7.  Filovirus pathogenesis and immune evasion: insights from Ebola virus and Marburg virus.

Authors:  Ilhem Messaoudi; Gaya K Amarasinghe; Christopher F Basler
Journal:  Nat Rev Microbiol       Date:  2015-10-06       Impact factor: 60.633

8.  The UK's multidisciplinary response to an Ebola epidemic.

Authors:  Sian Reece; Colin S Brown; Jake Dunning; Meera A Chand; Maria C Zambon; Michael Jacobs
Journal:  Clin Med (Lond)       Date:  2017-07       Impact factor: 2.659

9.  Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Authors:  Nadia Wauquier; Pierre Becquart; Cindy Padilla; Sylvain Baize; Eric M Leroy
Journal:  PLoS Negl Trop Dis       Date:  2010-10-05

Review 10.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.